Trial With Gemcitabine and Rapamycin in Second Line of Metastatic Osteosarcoma
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
Multicenter and prospective phase II trial with gemcitabine and rapamycin in second line of
metastatic osteosarcoma. The study includes 6 cycles of the combination gemcitabine+rapamycin
in metastatic or unresectable osteosarcoma patients.